Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

efficacy in inflammatory bowel disease targets and look forward to future research to uncover the product's potential in this important therapeutic area."

About the Studies

Results from CLIN 1001-004 were presented at ACG in a poster entitled "Larazotide Acetate Prevents Immunologic Changes Induced by Gluten Challenge in Celiac Disease Patients" (Poster 446). The randomized, double-blind, placebo-controlled study was designed to evaluate the effects of larazotide acetate on the systemic immunologic changes induced by a two week gluten challenge in patients with celiac disease. Study results showed that larazotide acetate was well tolerated and showed signs of efficacy in preventing immunologic changes induced by gluten challenge in patients with celiac disease, consistent with the beneficial effects observed on intestinal permeability, signs and symptoms. Clinical findings included:

-- Gluten challenge in the placebo (control) group resulted in an increase in circulating regulatory T cells (CD4, CD25, FOX-P3+) and a decrease in B cells (CD3, CD19+). These changes were completely prevented in the group on larazotide acetate.

-- There was a small, not statistically significant increase in the anti-tTG titer in the placebo (control) group, which was prevented in the group on larazotide acetate.

-- Other trends in specific monocyte populations induced by gluten challenge were also prevented to varying extents by larazotide acetate.

The second presentation, "Larazotide Acetate, a Tight Junction Inhibitor Peptide, Inhibits Epithelial Permeability Induced by TNF-alpha and IL-4" (Poster 1052) included results from a study investigating the effect of larazotide acetate on tumor necrosis factor (TNF-alpha) and interleukin (IL-4) induced permeability. The study showed that larazotide acetate inhibited increased permeability mediated with TNF-alpha and IL-4, which suggests the potential of larazotide acetate as a therapeutic agent for
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014  Alexza ... that it is participating in two healthcare conferences during ... Conference and the Morgan Stanley Global Healthcare 2014 Conference. ... Morgan Stanley Conference.  The details on each event are ... Conference, Monday, August 11, 2014 in Boston ...
(Date:7/29/2014)... ROCKVILLE, Md. , July 29, 2014  Synthetic ... anti-infective biologic and drug candidates targeting specific pathogens that ... view of the unusual market activity in the Company,s ... Company in accordance with its usual practice. The Company ... unusual market activity. About Synthetic Biologics, Inc. ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), a ... announced robust record breaking quarterly earnings for September 2011. ... million in net income, a 219% increase in revenues ... quarter of 2010. This translates to earnings of about ...
... 2011 /PR Newswire-Asia/ – Global Pharm ... the "Company"), a growing vertically integrated pharmaceutical company ... Chinese Medicine ("TCM") processing, and herbal cultivation and ... Jilin, Guangdong and Shandong provinces, today announced its ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 2Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 3Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 4Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 5Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 6Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 7Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 8Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 9Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 10Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 11Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 12Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results 13
(Date:7/29/2014)... 30, 2014 VogueQueen.com, a well-known online ... the newest trends in garment fashion by providing graceful ... is selling an all-inclusive array of sexy dresses ... online, a lot of customers take price into consideration. ... That makes the purchase more affordable for all clients. ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that the ... specialist. Alison Freeman wanted to show her patients some alternative ... in finding out more about this method can easily access ... is currently available in online format. , In the eBook, ... medicine tips that can help them achieve a cure for ...
(Date:7/29/2014)... July 29, 2014 The Natural Multiple ... the inside story to Gary M. Levin’s cure program. ... cure method for this serious disorder. Levin says that ... conditions that can be found in patients. , ... surgeon. For many years, Levin has worked with patients ...
(Date:7/29/2014)... 29, 2014 DailyGossip.org reveals in its ... is a new method of naturally overcoming sciatica, in ... the new method ensure sufferers that the cure is ... , The new method is described as very ... sciatica with an 8 minutes per day treatment plan. ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... want nothing more than to get back home to ... be more emotionally taxing than the deployment. Returning ... depressive symptoms and relationship distress, and research shows the ... Leanne Knobloch (pronounced kuh-NO-block). That,s not a good thing, ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Using ... strain of bacteria thought to be responsible for the Black ... The plague, caused by a strain of flea-borne bacteria ... centuries ago. But the variant of the bacterium behind that ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Nearly one ... age of 18, a new study finds, and they could face ... The research doesn,t prove that so-called "child marriage" causes ... report published in the September issue of the journal Pediatrics ...
... not how old but how frail patients are that can predict ... young patients in poor health may have worse outcomes than older ... University of Michigan Comprehensive Cancer Center finds that patients with decreased ... to distant parts of the body. These findings may ...
... of measles have been reported in the United States ... in Europe, a sign the disease is making an ... is the result of unfounded fears about a link ... some parents against childhood vaccination, says Gregory Poland, M.D. ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) ... to Iraq, Afghanistan or other war-torn countries may prime ... (PTSD), but new research suggests these changes don,t last ... anxiety disorder that develops after witnessing or surviving a ...
Cached Medicine News:Health News:Study offers insight for returning troops and their relationships 2Health News:Study offers insight for returning troops and their relationships 3Health News:Bacterial Strain Behind 'Black Death' Plague Is Likely Extinct: Study 2Health News:Bacterial Strain Behind 'Black Death' Plague Is Likely Extinct: Study 3Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 2Health News:Women Married Before Age 18 at Higher Risk of Mental Woes: Study 3Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News:Mayo Clinic physician: Mistaken fear of measles shot has 'devastating' effect 2Health News:Effects of Combat Stress May Not Last as Long as Thought 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: